Work

OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis (039)

Year: 2022

Type: article

Study design: Clinical Trial

Source: Gynecologic Oncology

DOI: 10.1016/s0090-8258(22)01258-6

Authors: Melissa Hardesty, Thomas Krivak, Gail Wright, Erika Hamilton, Evelyn Fleming, Jimmy Belotte, Erika Keeton, Ping Wang, Aine Clements, Heidi Gray, Gottfried Konecny, Richard Moore, Debra Richardson

Institutions: Alaska Women's Cancer Care, Western Pennsylvania Hospital, Florida Cancer Specialists & Research Institute, Tennessee Oncology, Dartmouth–Hitchcock Medical Center, Dartmouth Cancer Center, GlaxoSmithKline (United States), Riverside Methodist Hospital, University of Washington, University of California, Los Angeles, University of Rochester Medicine, University of Oklahoma Health Sciences Center

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4297769733

FWCI: 0.105

Cites:

Cited by: 1

Related to: 10